File(s) under permanent embargo
Fucoidan as an inhibitor of pro-inflammatory cytokines: potential candidate for treating inflammatory-related conditions
Material and methods:MTT cell viability assay was performed to assess the cytotoxicity of fucoidan extracts. Furthermore, a dose-response for fucoidan extracts was performed in LPS induced THP-1 cells and PBMCs after pre-treatment for 24 hours and levels of TNF-α, IL-1β, and IL-6 cytokines were measured using Enzyme-Linked Immunosorbent Assay (ELISA).
Results:MTT cell viability assay revealed that fucoidan extracts displayed no signs of cytotoxicity in THP-1 cells and PBMCs after incubation of 48 hours. Sandwich ELISA results exhibited that all fucoidan extracts reduced cytokine production in LPS stimulated PBMCs and human THP-1 cells in a dose-dependent fashion. Notably, the lower molecular fucoidan (5-30 kDa) extract from Macrocystis pyrifera was a highly effective inhibitor of pro-inflammatory cytokine at lower concentrations. Fucoidan extracts from all species demonstrated significant anti-inflammatory effects; however, the lower molecular weight extracts showed maximal effects at low concentrations. These observations on various fucoidan extracts offer insight into strategies that improve their efficacy against inflammation-related pathology.
Conclusion:We have successfully catalogued many fucoidan extracts based on their efficacy in LPS induced macrophages and PBMCs in down-regulating major pro-inflammatory cytokines (TNF-α, IL-1β, and IL-6), potential targets in human inflammatory conditions. Further investigation would provide additional insights about the mechanism of action to test for therapeutic applications as an anti-inflammatory medication.
Publication titleFASEB Journal
Department/SchoolSchool of Pharmacy and Pharmacology
Place of publicationUnited States
Event titleExperimental Biology 2022
Date of Event (Start Date)2022-04-02
Date of Event (End Date)2022-04-05